ClinicalTrials.gg
RecruitingNCT04712812HSPUpdated Mar 18, 2026

Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia

An observational study in Hereditary Spastic Paraplegia, SPG47 and SPG50, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
Up to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Spastic Paraplegia, Hereditary with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Spastic Paraplegia, Hereditary · United States.

Planned enrollment
3rd of 11
700 · median 200
Started
2020
the only one that year
Observational
11 of 18
4 open now
Registered
6th of 18
by date
Lead sponsor
3 of 18
Boston Children's Hospital

Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2020, is one of 11 observational ones, and was the 6th registered.

Spastic Paraplegia, Hereditary

51 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 20 are open to participants now.

Browse Spastic Paraplegia, Hereditary studies →

Open to participants now

7 of the 18 studies in Spastic Paraplegia, Hereditary with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Spastic Paraplegia, Hereditary studies recruiting now, 10 (59%) set no upper age limit and 7 (41%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: Up to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Spastic Paraplegia, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP with (1) a clinical diagnosis of hereditary spastic paraplegia and (2) the presence of variants in HSP related genes and/or be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into the registry for studies will advance knowledge of the causes, clinical course, diagnosis, and treatment of these conditions.

Read the detailed description

The hereditary spastic paraplegias (HSP) are a group of more than 80 neurodegenerative diseases that lead to progressive neurological decline. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability.

We aim to delineate the core clinical, imaging, and molecular features of pediatric onset hereditary spastic paraplegia. This registry and natural history study will facilitate an early diagnosis, enables counseling and anticipatory guidance of affected families and will help define clinically meaningful endpoints for future interventional trials. Samples will be collected for the purpose of molecular and cellular investigation that will help identify biomarkers and novel targets for therapy. The samples and clinical information will be housed in the Translational Neuroscience Center and a secure REDcap database, respectively; both located in Boston Children's Hospital (BCH), but will be available to investigators around the world after approval.

The objectives of this protocol are to (1) To systematically document the clinical presentation and natural history of early-onset forms of HSP and (2) To facilitate an early diagnosis, enable counseling and anticipatory guidance of affected families and help define clinically meaningful endpoints for future interventional traits.

Specifically, the aims are to:

  1. Establish the disease spectrum through a cross-sectional analysis of clinical, imaging and molecular data
  2. Establish the natural history of early-onset HSP through longitudinal clinician- and patient-reported outcome measures
  3. Create a biorepository (blood samples, fibroblasts, induced pluripotent stem cells)
  4. Create a registry that allows for re-identification and re-contact of participants by appropriate investigators
03

Conditions studied

  • Hereditary Spastic Paraplegia
  • SPG47
  • SPG50
  • SPG51
  • SPG52
  • AP4-related Hereditary Spastic Paraplegia
  • Early Onset Hereditary Spastic Paraplegia
  • SPG4
  • SPG3A
  • SPG15
  • SPG11

Keywords

  • AP4-HSP
  • AP4
  • SPG
  • AP-4
  • AP-4-HSP
  • Spastic Paraplegia
  • Adapter Protein 4
  • HSP
  • Early onset
  • Early onset HSP
04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Onset of hereditary spastic paraplegia symptoms before the age of 18 years
  • Under the age of 30 years old
  • Must have a genetically confirmed variant in HSP-related genes and a relative of an individual with a confirmed diagnosis (if applicable).

Exclusion criteria

Exclusion Criteria:

  • Not having such a diagnosis and/or not being related to such individual
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes

Groups and cohorts

  • Proband with Hereditary Spastic Paraplegia

    The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).

06

What researchers measure

Primary outcomes

  1. Establishment of disease spectrum

    Establish the disease spectrum through a cross-sectional analysis of clinical, imaging and molecular data

    Time frame: Through study completion, an average of 1 year

  2. Establishment of longitudinal data

    Establish the natural history of early-onset HSP through longitudinal clinician- and patient-reported outcome measures

    Time frame: Through study completion, an average of 1 year

  3. Creation of biorepository

    Create a biorepository (blood samples, fibroblasts, induced pluripotent stem cells)

    Time frame: Through study completion, an average of 1 year

  4. Creation of patient registry

    Create a registry that allows for re-identification and re-contact of participants by appropriate investigators

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Agianda HAP, Kim HM, Battaglia N, Rong J, Tam A, Gonzalez Saez-Diez E, Boerkoel CF, Saffari A, Quiroz V, Schierbaum L, Zaman Z, Bernardi K, Ebrahimi-Fakhari D. Diagnostic Utility of the ATG9A Ratio in AP-4-Associated Hereditary Spastic Paraplegia. Ann Clin Transl Neurol. 2026 Apr;13(4):834-839. doi: 10.1002/acn3.70308. Epub 2026 Jan 5. PubMed 41491634 ↗
  • Schmidt HJD, Battaglia N, Rong J, Tam A, Carty S, Quiroz V, Yang K, Zaman Z, Schierbaum L, Bernardi K, Alecu JE, Ebrahimi-Fakhari D. Health-Related Quality of Life in Rare Forms of Childhood-Onset Hereditary Spastic Paraplegia. Ann Clin Transl Neurol. 2026 Jan;13(1):193-199. doi: 10.1002/acn3.70244. Epub 2025 Nov 6. PubMed 41199121 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2020 (actual). Primary completion is estimated for Dec 2030, 128 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 15, 2021
StartActual
Apr 27, 2020
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04712812
Responsible party
Darius Ebrahimi-Fakhari (Director, Movement Disorders Program, Boston Children's Hospital) — Principal investigator
First posted
Jan 15, 2021
Start date
Apr 27, 2020
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 18, 2026

Study contacts

Darius Ebrahimi-Fakhari, MD, PhD
Contact
hsp.research@childrens.harvard.edu
617-355-6388
Nicole Battaglia, BS
Contact
hsp.research@childrens.harvard.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion